What is Immunic Therapeutics?
Immunic Therapeutics operates as a clinical-stage biopharmaceutical entity dedicated to the development of selective oral immunology therapies. The company's core focus lies in the treatment of chronic inflammatory and autoimmune diseases, a sector characterized by high barriers to entry and significant therapeutic demand. By prioritizing oral delivery mechanisms, Immunic aims to improve patient compliance and therapeutic outcomes compared to traditional injectable treatments. Its market position is defined by a rigorous scientific approach and a commitment to advancing a pipeline that addresses complex biological pathways involved in immune-mediated conditions.
How much funding has Immunic Therapeutics raised?
Immunic Therapeutics has raised a total of $1.1B across 4 funding rounds:
Share Placement
$60M
Multiple Rounds
$1B
Share Placement (2022): $60M, investors not publicly disclosed
Stock/Share Issuance (2026): $400M led by BVF Partners, Avidity Partners, Vivo Capital, TCG Crossover, and OrbiMed
Stock/Share Issuance (2026): $400M supported by BVF Partners
Private Equity (2026): $200M, investors not publicly disclosed
Key Investors in Immunic Therapeutics
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments with a focus on long-term value creation.
Vivo Capital
Vivo Capital is a global healthcare investment firm headquartered in Palo Alto, focusing on private and public equity as well as venture capital within the life sciences sector.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
What's next for Immunic Therapeutics?
Looking ahead, the infusion of capital will likely be directed toward the expansion of clinical trial programs and the optimization of the company's lead therapeutic candidates. As Immunic Therapeutics transitions through its current lifecycle stage, the focus will shift toward achieving key regulatory milestones and demonstrating the efficacy of its oral immunology platform in larger patient cohorts. The strategic support from its investor base provides not only the necessary financial runway but also the operational expertise required to navigate the complexities of late-stage drug development and eventual commercialization. The company remains poised to disrupt the standard of care for patients suffering from debilitating autoimmune disorders.
See full Immunic Therapeutics company page
